The inflammasome: an emerging therapeutic oncotarget for cancer prevention.
The inflammasome: an emerging therapeutic oncotarget for cancer prevention.
复制标题
DOI：
10.18632/oncotarget.9391
复制
发表时间：
2016-08-02
期刊：
影响因子：
--
通讯作者：
Lin Y
中科院分区：
文献类型：
--
作者：
Zhiyu W;Wang N;Wang Q;Peng C;Zhang J;Liu P;Ou A;Zhong S;Cordero MD;Lin Y
炎症失调被认为是癌症发生和发展调节的标志之一。越来越多的证据表明，炎性小体在调节与癌症相关的免疫细胞和细胞因子中起着核心作用。炎性小体是由NOD样受体（NLR）组成的多聚体复合物，并响应于多种内源性（损伤相关分子模式）和外源性（病原体相关分子模式）刺激。多条证据表明，在癌症中，炎性小体与诸如IL-1β和IL-18水平升高、NF-κB信号传导激活、线粒体氧化应激增强和自噬过程激活等特征正相关。许多NLR，如NLRP 3和NLRC 4也在癌发生中突出显示，并与化疗反应和预后密切相关。尽管有相互矛盾的证据表明炎性小体在癌症发展中的双重作用，但这种现象可能归因于NLR差异、细胞和组织类型、癌症阶段和特定的实验条件。鉴于炎性小体在介导癌症发展中的有前途的作用，精确阐明其信号网络和病理学意义可能会导致恶性肿瘤治疗和预防的新的治疗选择。
Deregulated inflammation is considered to be one of the hallmarks of cancer initiation and development regulation. Emerging evidence indicates that the inflammasome plays a central role in regulating immune cells and cytokines related to cancer. The inflammasome is a multimeric complex consisting of NOD-like receptors (NLRs) and responds to a variety of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli. Several lines of evidence suggests that in cancer the inflammasome is positively associated with characteristics such as elevated levels of IL-1β and IL-18, activation of NF-κB signaling, enhanced mitochondrial oxidative stress, and activation of autophagic process. A number of NLRs, such as NLRP3 and NLRC4 are also highlighted in carcinogenesis and closely correlate to chemoresponse and prognosis. Although conflicting evidence suggested the duplex role of inflammasome in cancer development, the phenomenon might be attributed to NLRs difference, cell and tissue type, cancer stage, and specific experimental conditions. Given the promising role of inflammasome in mediating cancer development, precise elucidation of its signaling network and pathological significance may lead to novel therapeutic options for malignancy therapy and prevention.